Loading…
Loading…
JAZZ does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for JAZZ and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for JAZZ and 80,000+ other tickers.
See exactly how JAZZ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for JAZZ and 80,000+ other tickers.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of…
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
DUBLIN, July 20, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 second quarter financial results on Monday, August 3, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals is testing a bull flag breakout following a long-term base advance, with confirmation needed above key swing resistance to validate continuation toward new highs.